Sanguina’s mission is to create a digital platform for diagnosing, monitoring, and managing wellness and chronic conditions. The company spun out of Georgia Institute of Technology, Emory University, Children’s Healthcare of Atlanta and the Centers for Disease Control and Prevention (CDC) and incorporated in 2019.

Sanguina’s first digital health platform app, AnemoCheck, estimates hemoglobin level and helps users manage anemia. Anemia, characterized by low hemoglobin levels, affects over 1.6bn individuals each year and has always been a marker of both illness and wellness, as it coexists with many chronic diseases and can guide treatment regimens.

Anemia management is integral to preventative and personalized medicine and driven by gains in home testing and artificial intelligence. In 2024 Sanguina is to release several upgrades to the existing product suite, including artificial intelligence and machine learning models for improved utility, performance, and broader accessibility, and paves the way for launch of new biomarkers and indications including home-based testing for circulation, dehydration, and management in the oncology space. With its successful launch of anemia testing Sanguina has taken a major step toward its goal of building a leading platform for home-based testing to manage wellness and chronic conditions.